Brixadi (Buprenorphine) Patent Expiration, LOE Window & CMS Spending

Brixadi (Buprenorphine) by Braeburn: FDA Orange Book LOE 2032-07-26, 12 AB generics, $126.4M 2024 CMS Part D & Medicaid spend, and $1,595 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBraeburn
FDA Application & PathwayN210136 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2032-07-26
Orange Book Patents (*PED Extensions)8 patents (0 *PED)
Active AB-Rated Generic Competitors12
2024 CMS Total Public Spend$126.4M
2024 Medicare Part D Spend$11.2M
2024 Medicaid Spend$115.2M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($1,595 intro WAC)